Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension
Links shared publicly online about this topic.
- 665total visits
Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension
View full resource at news-medical.net
Tags: Heart Disease, High Blood Pressure, Drug, Pharma, Phase 1 Clinical Trial, Clinical Trial, Pulmonology
Most Recently Shared on December 10, 2010 at 2:26 pm By:
Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension: Arena Pharmaceutica... http://bit.ly/dYzsFz
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial Of APD811 For Pulmonary Arterial Hypertension - QualityPoint Technologies
qualitypointtech.net — “Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH.” View full resource at qualitypointtech.net
Most Recently Shared on December 11, 2010 at 2:04 pm By:
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial Of APD811 For Pulmonary Arterial Hypertension: Arena Pharma... http://bit.ly/fS61b2
Phase 1 study of APD811 for pulmonary arterial hypertension (PAH) - MPR
empr.com — “Arena Pharmaceuticals announced the initiation of dosing in a Phase 1 clinical trial of APD811 for the treatment of pulmonary arterial hypertension (PAH).” View full resource at empr.com
Most Recently Shared on December 10, 2010 at 4:02 pm By:
MPR News: Phase 1 study of APD811 for pulmonary arterial hypertension (PAH): Arena Pharmaceuticals announced the... http://bit.ly/gB1o5i
Phase 1 study of APD811 for pulmonary arterial hypertension (PAH) - ONA
oncologynurseadvisor.com — “Arena Pharmaceuticals announced the initiation of dosing in a Phase 1 clinical trial of APD811 for the treatment of pulmonary arterial hypertension (PAH).” View full resource at oncologynurseadvisor.com
Most Recently Shared on December 10, 2010 at 3:37 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 1 study of APD811 for pulmonary arterial hypertension (PAH) http://goo.gl/fb/WCM0T
Advertisement
